Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
The NHS Commissioning Body (operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
UK
Contact person: Philip Grieve
E-mail: philip.grieve@nhs.net
NUTS: UK
Internet address(es)
Main address: https://www.england.nhs.uk/
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS National Framework Agreement for the Supply of Products for the Treatment of Haemophilia A
Reference number: CM/PHS/17/5564
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS national framework agreement for the supply of products for the treatment of Haemophilia A. The framework agreement is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1 July 2020 for a period of 24 months until 30 June 2022, with options to extend up to a maximum period of 24 months. Please refer to the invitation to offer documents for the list of purchasing points.
II.1.6) Information about lots
This contract is divided into lots:
Yes
II.1.7) Total value of the procurement
Value excluding VAT:
334 400 000.00
GBP
II.2) Description
Lot No: 1
II.2.1) Title
Plasma Derived Factor VIII
II.2.2) Additional CPV code(s)
33141510
33141530
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to the invitation to offer documents for the list of purchasing points.
II.2.4) Description of the procurement
NHS national framework agreement for the supply of products for the treatment of Haemophilia A. The framework agreement is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1 July 2020 for a period of 24 months until 30 June 2022, with options to extend up to a maximum period of 24 months.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Standard Half-life Recombinant Factor VIII
II.2.2) Additional CPV code(s)
33141530
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to the invitation to offer documents for the list of purchasing points.
II.2.4) Description of the procurement
NHS national framework agreement for the supply of products for the treatment of Haemophilia A. The framework agreement is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1 July 2020 for a period of 24 months until 30 June 2022, with options to extend up to a maximum period of 24 months.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Enhanced Half-life Recombinant Factor VIII
II.2.2) Additional CPV code(s)
33141530
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to the invitation to offer documents for the list of purchasing points.
II.2.4) Description of the procurement
NHS national framework agreement for the supply of products for the treatment of Haemophilia A. The framework agreement is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1 July 2020 for a period of 24 months until 30 June 2022, with options to extend up to a maximum period of 24 months.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
Emicizumab
II.2.2) Additional CPV code(s)
33141530
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to the invitation to offer documents for the list of purchasing points.
II.2.4) Description of the procurement
NHS national framework agreement for the supply of products for the treatment of Haemophilia A. The framework agreement is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1 July 2020 for a period of 24 months until 30 June 2022, with options to extend up to a maximum period of 24 months.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: as above
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2020/S 040-095840
IV.2.9) Information about termination of call for competition in the form of a prior information notice
The contracting authority will not award any further contracts based on the above prior information notice
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Bio Products Laboratory Ltd
Dagger Lane
Elstree
WD6 3BX
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Biotest (UK) Ltd
First Floor, Park Point, 17 High Street, Longbridge
Birmingham
B31 2UQ
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Grifols UK Ltd
Byron House, Cambridge Business Park
Cambridge
CB4 0WZ
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Novo Nordisk Ltd
3 City Place, Beehive Ring Road
Gatwick
RH6 0PA
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Octapharma Ltd
The Zenith Building, 26 Spring Gardens
Manchester
M2 1AB
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Pfizer Ltd
Walton Oaks, Dorking Road, Walton-on-the Hill
Tadworth
KT20 7NS
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Roche Products Ltd
6 Falcon Way, Shire Park
Welwyn Garden City
AL7 1TW
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Shire Pharmaceuticals Ltd
1 Kingdom Street
London
W2 6BD
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
03/06/2020
V.2.2) Information about tenders
Number of tenders received: 9
Number of tenders received from SMEs: 3
Number of tenders received by electronic means: 9
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Swedish Orphan Biovitrum Ltd (Sobi UK)
Suite 2, Riverside 3, Granta Park, Great Abington
Cambridge
CB21 6AD
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
The suppliers selected to participate in this framework agreement are:
Bio Products Laboratory Ltd
Biotest (UK) Ltd
Grifols UK Ltd
Novo Nordisk Ltd
Octapharma Ltd
Pfizer Ltd
Roche Products Ltd
Shire Pharmaceuticals Ltd
Swedish Orphan Biovitrum Ltd (Sobi UK).
VI.4) Procedures for review
VI.4.1) Review body
The Royal Courts of Justice
London or any of the district registry of the High Court
UK
VI.5) Date of dispatch of this notice
26/06/2020